vs
Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -1.7%, a 0.8% gap on every dollar of revenue. On growth, AVALON HOLDINGS CORP posted the faster year-over-year revenue change (21.7% vs -25.7%). AVALON HOLDINGS CORP produced more free cash flow last quarter ($-166.0K vs $-15.8M). Over the past eight quarters, AVALON HOLDINGS CORP's revenue compounded faster (6.7% CAGR vs -15.9%).
Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AWX vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.5M | $18.7M |
| Net Profit | $-356.0K | $-154.0K |
| Gross Margin | 17.1% | — |
| Operating Margin | 0.4% | -6.9% |
| Net Margin | -1.7% | -0.8% |
| Revenue YoY | 21.7% | -25.7% |
| Net Profit YoY | 28.4% | 97.6% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.5M | — | ||
| Q3 25 | $25.7M | — | ||
| Q2 25 | $20.3M | $18.7M | ||
| Q1 25 | $16.1M | $50.9M | ||
| Q4 24 | $17.6M | $38.1M | ||
| Q3 24 | $24.2M | $33.4M | ||
| Q2 24 | $23.1M | $25.1M | ||
| Q1 24 | $18.9M | $41.5M |
| Q4 25 | $-356.0K | — | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $274.0K | $-154.0K | ||
| Q1 25 | $-1.5M | $23.5M | ||
| Q4 24 | $-497.0K | $18.9M | ||
| Q3 24 | $1.8M | $5.7M | ||
| Q2 24 | $954.0K | $-6.5M | ||
| Q1 24 | $-979.0K | $13.8M |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 23.7% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.6% | — | ||
| Q2 24 | 22.1% | — | ||
| Q1 24 | 16.2% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 9.1% | — | ||
| Q2 25 | 3.7% | -6.9% | ||
| Q1 25 | -7.2% | 44.4% | ||
| Q4 24 | -0.8% | 46.4% | ||
| Q3 24 | 9.4% | 12.3% | ||
| Q2 24 | 6.3% | -33.7% | ||
| Q1 24 | -2.7% | 28.1% |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | 1.4% | -0.8% | ||
| Q1 25 | -9.3% | 46.2% | ||
| Q4 24 | -2.8% | 49.6% | ||
| Q3 24 | 7.6% | 17.2% | ||
| Q2 24 | 4.1% | -26.0% | ||
| Q1 24 | -5.2% | 33.3% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $38.4M | $119.9M |
| Total Assets | $87.4M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $3.7M | $49.0M | ||
| Q1 25 | $1.3M | $47.6M | ||
| Q4 24 | $2.8M | $38.1M | ||
| Q3 24 | $3.9M | $40.6M | ||
| Q2 24 | $3.8M | $43.2M | ||
| Q1 24 | $1.2M | $36.2M |
| Q4 25 | $38.4M | — | ||
| Q3 25 | $38.7M | — | ||
| Q2 25 | $36.8M | $119.9M | ||
| Q1 25 | $36.5M | $25.0M | ||
| Q4 24 | $38.0M | $-456.0K | ||
| Q3 24 | $38.5M | $-23.5M | ||
| Q2 24 | $36.7M | $-31.2M | ||
| Q1 24 | $35.7M | $-31.7M |
| Q4 25 | $87.4M | — | ||
| Q3 25 | $90.7M | — | ||
| Q2 25 | $88.1M | $175.1M | ||
| Q1 25 | $87.6M | $98.5M | ||
| Q4 24 | $86.2M | $120.5M | ||
| Q3 24 | $89.1M | $139.0M | ||
| Q2 24 | $91.7M | $159.2M | ||
| Q1 24 | $90.6M | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0K | $-15.8M |
| Free Cash FlowOCF − Capex | $-166.0K | $-15.8M |
| FCF MarginFCF / Revenue | -0.8% | -84.6% |
| Capex IntensityCapex / Revenue | 2.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.0K | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $3.0M | $-15.8M | ||
| Q1 25 | $-982.0K | $-21.0M | ||
| Q4 24 | $-579.0K | $-19.9M | ||
| Q3 24 | $342.0K | $-20.7M | ||
| Q2 24 | $3.2M | $-19.5M | ||
| Q1 24 | $411.0K | $-26.0M |
| Q4 25 | $-166.0K | — | ||
| Q3 25 | $852.0K | — | ||
| Q2 25 | $2.7M | $-15.8M | ||
| Q1 25 | $-1.4M | $-21.2M | ||
| Q4 24 | $-1.1M | $-20.0M | ||
| Q3 24 | $-660.0K | $-20.7M | ||
| Q2 24 | $2.9M | $-19.6M | ||
| Q1 24 | $56.0K | $-26.2M |
| Q4 25 | -0.8% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 13.5% | -84.6% | ||
| Q1 25 | -8.5% | -41.6% | ||
| Q4 24 | -6.4% | -52.5% | ||
| Q3 24 | -2.7% | -62.1% | ||
| Q2 24 | 12.4% | -78.2% | ||
| Q1 24 | 0.3% | -63.1% |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.4% | 0.1% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 3.1% | 0.2% | ||
| Q3 24 | 4.1% | 0.1% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 1.9% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | 0.19× | -3.61× | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AWX
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
